INDICATIONS     CONTRA-INDICATIONS     DOSAGE     SIDE-EFFECTS     PREGNANCY     OVERDOSE     IDENTIFICATION     PATIENT INFORMATION
BICILLIN® L-A 1,2 Injection
BICILLIN® L-A 2,4 Injection

SCHEDULING STATUS:
S4

PROPRIETARY NAME
(and dosage form):

BICILLIN^® L-A 1,2 Injection
BICILLIN^® L-A 2,4 Injection

COMPOSITION:
BICILLIN L-A 1,2 m units:
When reconstituted with 3 mL water for injection the contents of each vial provides 4 mL containing 1,2 m units Benzathine penicillin G with 0,45% m/m methylparaben and 0,053% m/m propylparaben as preservatives.

BICILLIN L-A 2,4 m units:
When reconstituted with 6 mL water for injection the contents of each vial provides 8 mL containing 2,4 m units Benzathine penicillin G with 0,45% m/m methylparaben and 0,053 % m/m propylparaben as preservatives.

PHARMACOLOGICAL CLASSIFICATION:
Category A, 20.1.2 Antimicrobial (Chemotherapeutic) agents.
Penicillins.

PHARMACOLOGICAL ACTION:
Penicillin inhibits, in susceptible bacteria, the synthesis of peptidoglycan, a complex macromolecule which forms one layer of the cell wall of both gram-positive and gram-negative micro-organisms. Peptidoglycan provides rigid mechanical stability by virtue of its highly cross-linked latticework structure. Deprived of its rigid cell wall, the bacterial cell loses the protection it requires because of its high intracellular osmotic pressure. Lysis of the cell membrane and death follows.

Benzathine penicillin G is slowly absorbed from intramuscular depots and produces the longest duration of detectable antibiotic of all the available repository penicillins.

INDICATIONS:
For the treatment of infections caused by organisms sensitive to penicillin G.

CONTRA-INDICATIONS:
Hypersensitivity to penicillin.

DOSAGE AND DIRECTIONS FOR USE:
Treatment of streptococcal infections:
A single dose of 600 000 to 900 000 units for children and 900 000 to 1200 000 units for adults is recommended. If necessary, the dose may be repeated as required.

Treatment of susceptible staphylococcal infections:
Administer 1200 000 units and repeat in 48 to 72 hours if required.

Treatment of pneumococcal infections (except pneumococcal meningitis):
One dose of 600 000 units, repeated in 24 hours suffices for mild or moderate cases.
In severe infections, this dose should be repeated every other day until the temperature has been normal for 48 hours.

Treatment of secondary bacterial infections:
In many viral infections an injection of 600 000 units is useful in the treatment of complications from secondary bacterial infections.

Treatment of gonorrhoea:
One dose of 600 000 to 1 200 000 units is usually effective.

Treatment of syphilis:

	TOTAL DOSAGE
PRIMARY AND SECONDARY SYPHILIS	2,4 m units given in a single dose (by injecting 1,2 m units in each buttock).
LATENT SYPHILIS	4,8 m units given in 2 doses, each 2,4 m units (1,2 m units in each buttock), at an interval of 7 days.
LATE SYPHILIS Benign (cutaneous, osseous, and visceral gumma) Cardiovascular Syphilis (symptomatic and symptomatic)	6 to 9 m units, administered in doses of 3 m units (1,5 m units in each buttock), at intervals of 7 days.

		TOTAL DOSAGE
CONGENITAL SYPHILIS		0,6 to 1,2 m units at intervals of one to two weeks until total dosage is given.
(a) Early congenital syphilis (under 2 years of age	Age	Units per kg of body mass	Average total dose
	0-6 months	75 000	1,5 m units
	7-12 months	65 000	2,4 m units
	12-24 months	60 000	3,0 m units
(b) Late congenital syphilis (over 2 years of age
	2 - 4 years	50 000	3,6 m units
	5 - 12 years	30 000
		40 000	to 4,8 m units
	Over 12 years	25 000
		30 000	to 6,0 m units

General Prophylaxis.
A single dose of 600 000 units is recommended, e.g. administer one day prior to tooth extraction or tonsillectomy.

Prophylaxis in rheumatic fever:
For the specific purpose of preventing recurrent attacks of rheumatic fever, a 1 200 000 unit dose is repeated every four weeks. Prophylaxis should be continued indefinitely.

BICILLIN L-A must be administered by deep intramuscular injection in the upper outer quadrant of the buttock. In infants and small children, the midlateral aspect of the thigh may be preferable.

SIDE-EFFECTS AND SPECIAL PRECAUTIONS:
In rare instances the injection of penicillin may cause acute anaphylaxis which may prove fatal unless promptly controlled. This type of reaction appears more frequently in patients with previous sensitivity reactions to penicillin, and in those with bronchial asthma or other allergies. Resuscitative medicines such as adrenaline, aminophylline and pressor amines should be readily available for emergency administration.

Other hypersensitivity reactions which may occur are: skin rashes, contact dermatitis, oral lesions, fever, eosinophilia, interstitial nephritis, angioedema serum sickness and the Arthus phenomenon. Care should be taken to avoid accidental intravenous or intra-arterial administration.

KNOWN SYMPTOMS OF OVERDOSAGE AND PARTICULARS OF ITS TREATMENT:
Treatment is symptomatic and supportive.

CONDITIONS OF REGISTRATION:
May be advertised to the professions only.

IDENTIFICATION:
BICILLIN L-A injections are supplied in vials of sterile dry white powder.

PRESENTATION:
BICILLIN L-A injections are supplied in vials of 1,2 m units and 2,4 m units.

STORAGE DIRECTIONS:
Store in a cool (below 25°C) place.
Keep out of reach of children.
Administer suspension within 24 hours after reconstitution.
Discard any unused portion.

REFERENCE NUMBERS:
BICILLIN L-A 1,2: A6 (Act 101/1965)
BICILLIN L-A 2,4: A820 (Act 101/1965)

NAME AND BUSINESS ADDRESS OF APPLICANT:
AKROMED PRODUCTS (PTY) LTD.
Electron Avenue ISANDO 1600
Trademark and product under licence from
WYETH-AYERST LABORATORIES, U.S.A.

DATE OF PUBLICATION OF THIS PACKAGE INSERT:
April 1968

        NDC B-397 A (1,2)
        NDC B-397 B (2,4)
        586-517
        Davbar Dbn.
SAEPI HOME PAGE      TRADE NAME INDEX      GENERIC NAME INDEX      FEEDBACK
Information presented by Malahyde Information Systems © Copyright 1996-2000